The 29th Annual Meeting of the Korean College of Helicobacter and Upper Gastrointestinal Research & the 3rd Seoul International Symposium on Helicobacter and Upper Gastrointestinal Diseases

Scientific Program

Program Details

> Scientific Program > Program Details

Plenary Session and YIA Ceremony Day 2_ 20(Sat.) 15:20 - 17:10

15:20-15:31 YIA-01 (Abstract No. A-0140)
Ga Hee Kim (Asan Medical Cancer, Korea)
Evaluation of endoscopic and clinicopathologic features of eosinophilic gastritis in Korea
following Western consensus guideline: A pilot study

15:31-15:42 YIA-02
Takako Takayama (University of Tsukuba, Japan)
Prediction of true uninfected (true Group A) by using combination of H. pylori antibody,
serum pepsinogen, and other factors: a logistic regression analysis

15:42-15:53 YIA-03 (Abstract No. A-0155)
Youn I Choi (Gachon University, Gil Medical Center, Korea)
Therapeutic Potential of Sitafloxacin as a new drug candidate for Helicobacter Eradication in Korea:
In vitro Culture-based Study

15:53-16:04 YIA-04
Kohei Yasuda (Hirosaki University, Japan)
Comparison of body weight and serum pepsinogen levels after Helicobacter pylori eradication therapy
by ABC classification

16:04-16:15 YIA-05 (Abstract No. A-0069)
Haeng Dueng Jeong (Yonsei University, Korea)
WFDC2 promotes spasmolytic polypeptide-expressing metaplasia through the upregulation of IL33
in response to gastric injury

16:15-16:26 YIA-06
Kartika Fauzia (Oita University, Japan)
Development of a Helicobacter pylori East Asian-type CagA Immunochromatography Assay for
Rapid Detection of Antibody in Serum

16:26-16:37 YIA-07 (Abstract No. A-0002)
Tae Jun Kim (Samsung Medical Center, Korea)
Statin use and the risk of metachronous gastric cancer in patients without Helicobacter pylori infection

16:37-16:48 YIA-08
Hiroyuki Eto (Chichibu Municipal Hospital, Japan)
BMI associates to the eradication rate of vonoprazan-based dual therapy in first-line
Helicobacter pylori treatment

16:48-16:59 YIA-09 (Abstract No. A-0076)
Jong Yeul Lee (National Cancer Center, Korea)
Effects of Helicobacter pylori Therapy on Glandular Atrophy and Intestinal Metaplasia after Endoscopic Resection for Gastric Neoplasm: Follow-up of a Randomized Controlled Trial

16:59-17:10 YIA-10
Yasuhiro Wada (Oita University, Japan)
Histological changes focused on pyloric and pseudopyloric metaplasia after Helicobacter pylori eradication

Korean College of Helicobacter and Upper Gastrointestinal Research
Room 305, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
TEL: +82-2-565-9946 FAX: +82-2-565-9947 E-mail: hpylori@kams.or.kr
대한상부위장관∙헬리코박터학회 / 대표자:김재규 / 사업자번호:106-82-61000 / 주소 : 서울시 강남구 선릉로 86길 31, 305호 / 전화:02-565-9946

HUG 2021 Secretariat : MediOffice
Tel : +82-2-459-8252
Fax : +82-2-459-8256
Email: helicobacter@medioffice.or.kr

15:20-15:31	YIA-01 (Abstract No. A-0140) Ga Hee Kim (Asan Medical Cancer, Korea) Evaluation of endoscopic and clinicopathologic features of eosinophilic gastritis in Korea following Western consensus guideline: A pilot study
15:31-15:42	YIA-02 Takako Takayama (University of Tsukuba, Japan) Prediction of true uninfected (true Group A) by using combination of H. pylori antibody, serum pepsinogen, and other factors: a logistic regression analysis
15:42-15:53	YIA-03 (Abstract No. A-0155) Youn I Choi (Gachon University, Gil Medical Center, Korea) Therapeutic Potential of Sitafloxacin as a new drug candidate for Helicobacter Eradication in Korea: In vitro Culture-based Study
15:53-16:04	YIA-04 Kohei Yasuda (Hirosaki University, Japan) Comparison of body weight and serum pepsinogen levels after Helicobacter pylori eradication therapy by ABC classification
16:04-16:15	YIA-05 (Abstract No. A-0069) Haeng Dueng Jeong (Yonsei University, Korea) WFDC2 promotes spasmolytic polypeptide-expressing metaplasia through the upregulation of IL33 in response to gastric injury
16:15-16:26	YIA-06 Kartika Fauzia (Oita University, Japan) Development of a Helicobacter pylori East Asian-type CagA Immunochromatography Assay for Rapid Detection of Antibody in Serum
16:26-16:37	YIA-07 (Abstract No. A-0002) Tae Jun Kim (Samsung Medical Center, Korea) Statin use and the risk of metachronous gastric cancer in patients without Helicobacter pylori infection
16:37-16:48	YIA-08 Hiroyuki Eto (Chichibu Municipal Hospital, Japan) BMI associates to the eradication rate of vonoprazan-based dual therapy in first-line Helicobacter pylori treatment
16:48-16:59	YIA-09 (Abstract No. A-0076) Jong Yeul Lee (National Cancer Center, Korea) Effects of Helicobacter pylori Therapy on Glandular Atrophy and Intestinal Metaplasia after Endoscopic Resection for Gastric Neoplasm: Follow-up of a Randomized Controlled Trial
16:59-17:10	YIA-10 Yasuhiro Wada (Oita University, Japan) Histological changes focused on pyloric and pseudopyloric metaplasia after Helicobacter pylori eradication